vs
Encompass Health Corp（EHC）とアイエフエフ（IFF）の財務データ比較。上の社名をクリックして会社を切り替えられます
アイエフエフの直近四半期売上が大きい（$2.6B vs $1.5B、Encompass Health Corpの約1.7倍）。Encompass Health Corpの純利益率が高く（9.5% vs 0.2%、差は9.3%）。Encompass Health Corpの前年同期比売上増加率が高い（9.9% vs -6.6%）。アイエフエフの直近四半期フリーキャッシュフローが多い（$130.0M vs $116.7M）。過去8四半期でEncompass Health Corpの売上複合成長率が高い（8.3% vs -5.5%）
エンコンパスヘルスコーポレーション（旧Amcare、HealthSouth）は米国アラバマ州バーミンガムに本社を置く米国最大の入院リハビリサービス事業者で、39州とプエルトリコに173の入院リハビリ病院を展開し、脳卒中や神経疾患、心肺疾患、脳損傷から回復中の患者に専門的な治療とケアを提供している。
インターナショナル・フレーバー・アンド・フレグランス（IFF）は米国企業で、風味、食感、香り、栄養、酵素、菌種、大豆たんぱく質、プロバイオティクスなどの分野で商品を開発し、世界中で販売しています。本社はニューヨークにあり、44カ国に開発・営業・生産拠点を構え、S&P500種株価指数の採用銘柄です。
EHC vs IFF — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $1.5B | $2.6B |
| 純利益 | $146.1M | $5.0M |
| 粗利率 | — | 34.4% |
| 営業利益率 | 16.7% | 3.7% |
| 純利益率 | 9.5% | 0.2% |
| 売上前年比 | 9.9% | -6.6% |
| 純利益前年比 | 20.8% | 110.9% |
| EPS（希薄化後） | $1.43 | $0.03 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $1.5B | $2.6B | ||
| Q3 25 | $1.5B | $2.7B | ||
| Q2 25 | $1.5B | $2.8B | ||
| Q1 25 | $1.5B | $2.8B | ||
| Q4 24 | $1.4B | $2.8B | ||
| Q3 24 | $1.4B | $2.9B | ||
| Q2 24 | $1.3B | $2.9B | ||
| Q1 24 | $1.3B | $2.9B |
| Q4 25 | $146.1M | $5.0M | ||
| Q3 25 | $126.5M | $40.0M | ||
| Q2 25 | $142.1M | $612.0M | ||
| Q1 25 | $151.5M | $-1.0B | ||
| Q4 24 | $120.9M | $-46.0M | ||
| Q3 24 | $108.2M | $59.0M | ||
| Q2 24 | $114.1M | $170.0M | ||
| Q1 24 | $112.5M | $60.0M |
| Q4 25 | — | 34.4% | ||
| Q3 25 | — | 36.5% | ||
| Q2 25 | — | 37.3% | ||
| Q1 25 | — | 36.4% | ||
| Q4 24 | — | 35.4% | ||
| Q3 24 | — | 36.0% | ||
| Q2 24 | — | 37.0% | ||
| Q1 24 | — | 35.3% |
| Q4 25 | 16.7% | 3.7% | ||
| Q3 25 | 14.9% | 8.4% | ||
| Q2 25 | 16.2% | 7.2% | ||
| Q1 25 | 16.4% | -31.8% | ||
| Q4 24 | 14.3% | 4.6% | ||
| Q3 24 | 13.6% | 8.5% | ||
| Q2 24 | 14.3% | 6.6% | ||
| Q1 24 | 13.6% | 6.9% |
| Q4 25 | 9.5% | 0.2% | ||
| Q3 25 | 8.6% | 1.5% | ||
| Q2 25 | 9.7% | 22.1% | ||
| Q1 25 | 10.4% | -35.8% | ||
| Q4 24 | 8.6% | -1.7% | ||
| Q3 24 | 8.0% | 2.0% | ||
| Q2 24 | 8.8% | 5.9% | ||
| Q1 24 | 8.5% | 2.1% |
| Q4 25 | $1.43 | $0.03 | ||
| Q3 25 | $1.24 | $0.16 | ||
| Q2 25 | $1.39 | $2.38 | ||
| Q1 25 | $1.48 | $-3.98 | ||
| Q4 24 | $1.18 | $-0.17 | ||
| Q3 24 | $1.06 | $0.23 | ||
| Q2 24 | $1.12 | $0.66 | ||
| Q1 24 | $1.10 | $0.23 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $72.2M | $590.0M |
| 総負債低いほど良い | $2.4B | $5.6B |
| 株主資本純資産 | $2.4B | $14.2B |
| 総資産 | $7.1B | $25.5B |
| 負債/資本比率低いほどレバレッジが低い | 1.00× | 0.40× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $72.2M | $590.0M | ||
| Q3 25 | $48.7M | $621.0M | ||
| Q2 25 | $99.1M | $816.0M | ||
| Q1 25 | $95.8M | $613.0M | ||
| Q4 24 | $85.4M | $469.0M | ||
| Q3 24 | $147.8M | $567.0M | ||
| Q2 24 | $154.4M | $671.0M | ||
| Q1 24 | $134.4M | $732.0M |
| Q4 25 | $2.4B | $5.6B | ||
| Q3 25 | $2.4B | — | ||
| Q2 25 | $2.3B | — | ||
| Q1 25 | $2.3B | — | ||
| Q4 24 | $2.4B | $8.9B | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.7B | — | ||
| Q1 24 | $2.7B | — |
| Q4 25 | $2.4B | $14.2B | ||
| Q3 25 | $2.4B | $14.2B | ||
| Q2 25 | $2.3B | $14.4B | ||
| Q1 25 | $2.2B | $13.2B | ||
| Q4 24 | $2.1B | $13.9B | ||
| Q3 24 | $2.0B | $14.8B | ||
| Q2 24 | $1.8B | $14.3B | ||
| Q1 24 | $1.7B | $14.3B |
| Q4 25 | $7.1B | $25.5B | ||
| Q3 25 | $6.9B | $25.8B | ||
| Q2 25 | $6.8B | $26.1B | ||
| Q1 25 | $6.6B | $28.3B | ||
| Q4 24 | $6.5B | $28.7B | ||
| Q3 24 | $6.5B | $29.9B | ||
| Q2 24 | $6.4B | $29.5B | ||
| Q1 24 | $6.2B | $30.6B |
| Q4 25 | 1.00× | 0.40× | ||
| Q3 25 | 1.01× | — | ||
| Q2 25 | 1.02× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 1.14× | 0.64× | ||
| Q3 24 | 1.20× | — | ||
| Q2 24 | 1.46× | — | ||
| Q1 24 | 1.54× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $346.0M | $318.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $116.7M | $130.0M |
| FCFマージンFCF / 売上 | 7.6% | 5.0% |
| 設備投資強度設備投資 / 売上 | 14.8% | 7.3% |
| キャッシュ転換率営業CF / 純利益 | 2.37× | 63.60× |
| 直近12ヶ月FCF直近4四半期 | $439.2M | $256.0M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $346.0M | $318.0M | ||
| Q3 25 | $270.8M | $164.0M | ||
| Q2 25 | $270.2M | $241.0M | ||
| Q1 25 | $288.6M | $127.0M | ||
| Q4 24 | $278.8M | $368.0M | ||
| Q3 24 | $267.8M | $366.0M | ||
| Q2 24 | $217.4M | $237.0M | ||
| Q1 24 | $238.8M | $99.0M |
| Q4 25 | $116.7M | $130.0M | ||
| Q3 25 | $83.7M | $32.0M | ||
| Q2 25 | $113.3M | $146.0M | ||
| Q1 25 | $125.5M | $-52.0M | ||
| Q4 24 | $80.1M | $208.0M | ||
| Q3 24 | $120.3M | $263.0M | ||
| Q2 24 | $60.5M | $155.0M | ||
| Q1 24 | $99.4M | $-19.0M |
| Q4 25 | 7.6% | 5.0% | ||
| Q3 25 | 5.7% | 1.2% | ||
| Q2 25 | 7.8% | 5.3% | ||
| Q1 25 | 8.6% | -1.8% | ||
| Q4 24 | 5.7% | 7.5% | ||
| Q3 24 | 8.9% | 9.0% | ||
| Q2 24 | 4.6% | 5.4% | ||
| Q1 24 | 7.6% | -0.7% |
| Q4 25 | 14.8% | 7.3% | ||
| Q3 25 | 12.7% | 4.9% | ||
| Q2 25 | 10.8% | 3.4% | ||
| Q1 25 | 11.2% | 6.3% | ||
| Q4 24 | 14.1% | 5.8% | ||
| Q3 24 | 10.9% | 3.5% | ||
| Q2 24 | 12.1% | 2.8% | ||
| Q1 24 | 10.6% | 4.1% |
| Q4 25 | 2.37× | 63.60× | ||
| Q3 25 | 2.14× | 4.10× | ||
| Q2 25 | 1.90× | 0.39× | ||
| Q1 25 | 1.90× | — | ||
| Q4 24 | 2.31× | — | ||
| Q3 24 | 2.48× | 6.20× | ||
| Q2 24 | 1.91× | 1.39× | ||
| Q1 24 | 2.12× | 1.65× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
EHC
| Medicare | $1.0B | 66% |
| Medicare Advantage | $243.1M | 16% |
| Managed Care | $160.7M | 10% |
| Medicaid | $47.0M | 3% |
| Other Income Source | $44.8M | 3% |
| Other Thirdparty Payors | $11.2M | 1% |
| Workers Compensation | $7.6M | 0% |
| Patients | $4.6M | 0% |
IFF
| Food Ingredients | $802.0M | 31% |
| Scent | $610.0M | 24% |
| Other | $589.0M | 23% |
| Taste | $588.0M | 23% |
